India markets open in 6 hours 39 minutes
  • BSE SENSEX

    49,034.67
    -549.53 (-1.11%)
     
  • Nifty 50

    14,433.70
    -161.90 (-1.11%)
     
  • Dow

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • BTC-INR

    2,646,299.00
    +86,682.75 (+3.39%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • Hang Seng

    28,573.86
    +76.96 (+0.27%)
     
  • Nikkei

    28,519.18
    -179.12 (-0.62%)
     
  • EUR/INR

    88.3766
    -0.4557 (-0.51%)
     
  • GBP/INR

    99.3974
    -0.5993 (-0.60%)
     
  • AED/INR

    19.8740
    +0.0260 (+0.13%)
     
  • INR/JPY

    1.4161
    -0.0019 (-0.13%)
     
  • SGD/INR

    55.0230
    -0.1730 (-0.31%)
     

Lupin receives approval for Meloxicam capsules

·1-min read

The announcement was made after market hours yesterday, 2 June 2020. Shares of Lupin gained 2.59% to close at Rs 870.90 on 2 June 2020.

Lupin announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly.

Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain. Meloxicam Capsules had an annual sales of approximately $14 million in the U.S. (IQVIA MAT March 2020).

Lupin is a transnational pharmaceutical company headquartered in Mumbai. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.



Source: Capitalmarket.com